Recent Updates
Recently added Catalysts
MLYS Positive Sentiment Score: 75/100

Mineralys Therapeutics to Announce Topline Data from Launch-HTN and Advance-HTN Pivotal Trials Monday, March 10, 2025, at 8:00 AM ET

Friday, March 7, 2025 2 min read
Key Takeaway: Mineralys Therapeutics, Inc. will announce topline results from its pivotal trials, Launch-HTN and Advance-HTN, on March 10, 2025. The trials investigate lorundrostat, a selective aldosterone inhibitor, for treating uncontrolled hypertension as an add-on therapy. The company aims to address hypertension and other cardiorenal conditions driven by dysregulated aldosterone. The announcement will be made via a conference call and webcast, ensuring transparency with stakeholders.

Market Sentiment Analysis

POSITIVE FACTORS

  • Mineralys Therapeutics is advancing its pivotal trials for lorundrostat, which targets uncontrolled hypertension.
  • The upcoming announcement of topline data shows potential progress in addressing resistant hypertension.
  • The conference call allows for direct communication of results to stakeholders.

Full Press Release Details

RADNOR, Pa., March 07, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, today announced it will host a conference call and webinar to announce topline results from its Launch-HTN and Advance-HTN pivotal trials on Monday, March 10, 2025, at 8:00 a.m. ET.
The Launch-HTN trial evaluated the efficacy and safety of lorundrostat, a highly selective aldosterone inhibitor, for the treatment of uncontrolled hypertension (uHTN) or resistant hypertension (rHTN) as an add-on therapy to an existing, prescribed background treatment of two to five antihypertensive medications.
The Advance-HTN trial evaluated the efficacy and safety of lorundrostat for the treatment of uHTN or rHTN when used as an add-on therapy to a standardized background treatment of two or three anti-hypertensive medications.
Monday, March 10 th @ 8:00 a.m. ET
Domestic: 1-877-704-4453
International: 1-201-389-0920
Webcast: Link
A live webcast of the conference call may also be found on the “News & Events” page in the Investor Relations section of the Mineralys Therapeutics website.
About Mineralys Therapeutics
Mineralys Therapeutics is a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, CKD, OSA and other diseases driven by dysregulated aldosterone. Its initial product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that Mineralys Therapeutics is developing for cardiorenal conditions affected by dysregulated aldosterone, including hypertension, CKD and OSA. Mineralys is based in Radnor, Pennsylvania, and was founded by Catalys Pacific. For more information, please visit https://mineralystx.com. Follow Mineralys on LinkedIn and Twitter.
investorrelations@mineralystx.com
Elixir Health Public Relations
Phone: (1) 515-707-9678
Email: tweible@elixirhealthpr.com

Frequently Asked Questions

What is the focus of Mineralys Therapeutics?

Mineralys Therapeutics develops medicines targeting hypertension, CKD, and OSA.

When will the topline results be announced?

The topline results will be announced on March 10, 2025, at 8:00 a.m. ET.

What trials are being discussed for lorundrostat?

The Launch-HTN and Advance-HTN trials evaluate lorundrostat for hypertension.

What type of inhibitor is lorundrostat?

Lorundrostat is a highly selective aldosterone synthase inhibitor.

How can I access the conference call?

You can join the call by phone or via a webcast on their website.

Tags: MLYS Viatris Investor Conferences Healthcare lorundrostat hypertension pivotal trials clinical-stage biopharmaceutical
Last updated: Mar 7, 2025